Thoroughbred Financial Services LLC Invests $742,000 in argenx SE (NASDAQ:ARGX)

Thoroughbred Financial Services LLC purchased a new stake in shares of argenx SE (NASDAQ:ARGX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,208 shares of the company’s stock, valued at approximately $742,000.

Several other institutional investors have also added to or reduced their stakes in ARGX. Steward Partners Investment Advisory LLC raised its stake in shares of argenx by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock valued at $234,000 after acquiring an additional 20 shares during the last quarter. SG Americas Securities LLC lifted its holdings in argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after buying an additional 21 shares during the period. Farther Finance Advisors LLC grew its position in shares of argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after buying an additional 21 shares during the last quarter. Dynasty Wealth Management LLC grew its position in shares of argenx by 3.4% in the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock worth $416,000 after buying an additional 22 shares during the last quarter. Finally, Choreo LLC increased its stake in shares of argenx by 4.4% during the fourth quarter. Choreo LLC now owns 551 shares of the company’s stock valued at $342,000 after buying an additional 23 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Robert W. Baird lifted their price target on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a report on Tuesday, March 4th. Citigroup reaffirmed an “outperform” rating on shares of argenx in a research note on Friday, February 28th. JMP Securities increased their price target on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. Truist Financial reaffirmed a “buy” rating and set a $700.00 price objective (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Finally, Oppenheimer increased their target price on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Stock Performance

NASDAQ ARGX opened at $555.11 on Friday. argenx SE has a one year low of $352.77 and a one year high of $678.21. The stock has a 50-day moving average of $621.43 and a 200 day moving average of $603.18. The company has a market capitalization of $33.73 billion, a price-to-earnings ratio of -630.81 and a beta of 0.60.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. On average, equities analysts predict that argenx SE will post 3.13 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.